Indian Vaccine Market Top Companies, Investment Trend, Growth & Innovation Trends 2024

IMARC Group’s latest report, titled “Indian Vaccine Market Report and Forecast 2018-2023”, finds that the Indian vaccine market reached a value of INR 68.8 Billion in 2017, growing at a CAGR of nearly 18% during 2010-2017. Vaccines refer to biological preparations containing weakened or dead microbes which lead to immunization against specific diseases. They are administered orally, by aerosol or through injections to develop immunity in the body against a number of diseases such as polio, measles, influenza and rabies. Currently, India is one of the leading manufacturers and suppliers of vaccines in the world. It solely accounts for 60% of the total vaccines supplied to UNICEF.

Strong government support remains the primary growth driving factor.

Entry of private players has also contributed to the market growth.

Based on type, oral polio vaccine accounts for the majority of the market share.

One of the major drivers of the Indian vaccine market has been the strong government support. Sturdy government funding and successful initiative have resulted in massive market development. Government-funded health campaigns have created widespread health awareness among the population, resulting in the expansion of the consumer-base. Continuous R&D has led to the introduction of new and improved vaccines in the market, which has boosted their demand as well as the profits of the manufacturers. Rising interest of private players in vaccine manufacturing along with the growing mergers and acquisitions in the industry has also enhanced the production capacity of the producers, thus increasing the product supply in the international market. This has resulted in the massive growth of the vaccine market in India. Some of the other factors positively influencing the market growth are growing population, elevating incomes, improving cold chain logistics and NGO participation.

Request to get the sample pages: 

The market has been segmented on the basis of type, where oral polio vaccine accounts for the majority of the market share. The vaccines covered in the report include BCG, HIB, Influenza, Varicella, Typhoid, Japanese Encephalitis, Measles, Tetanus Toxoid, Hepatitis A, Rubella, DPT, Polio, MMR, Rotavirus, Hepatitis B, Pneumococcal, Meningococcal, Rabies and HPV. Some of the key players operating in the market represent Sanofi Aventis, Pfizer, Novartis, Serum Institute and Panacea Biotech.

Oral Polio Vaccine

Rabies Vaccine

Sanofi Aventis

Pfizer

Novartis

Serum Institute

Panacea Biotech

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

IMARC Group

Tel: +1-631-791-1145

Email: sales@imarcgroup.com

Website: https://www.imarcgroup.com

Follow us on twitter: @imarcglobal

Report this Page